Regional distribution of vasoactive intestinal peptide in brains from normal and parkinsonian subjects. 1988

S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
UA CNRS 650, Unité Alliée à l'INSERM Université de Rouen, Mont-Saint-Aignan, France.

The distribution of vasoactive intestinal peptide (VIP) in the post-mortem human brain was determined by radioimmunoassay using a highly specific antiserum. The detection limit of the assay was 4 fmol/tube. The highest concentrations of VIP were found in the cerebral cortex, amygdala, hypothalamus and hippocampus. The lowest levels of peptide were detected in basal ganglia including caudate nucleus, external pallidum, putamen and substantia nigra. All dilution curves of acetic acid extracts from different brain areas were strictly parallel to the standard curve. Sephadex G-50 gel filtration of frontal cortex extract showed that VIP-like immunoreactivity (VIP-LI) eluted as a major peak comigrating with synthetic hVIP. Detailed mapping of VIP in the human cerebral cortex showed the existence of a rostro-caudal gradient of VIP-LI concentrations: the frontal cortex exhibited the highest VIP levels, the parietal and temporal cortex contained medium values and the occipital cortex contained the lowest VIP levels. The concentrations of VIP-LI were compared in various regions of the human brain from normal and parkinsonian subjects. No significant changes in VIP-LI levels occurred in the brains of patients dying with Parkinson's disease. No difference in VIP levels could be found either when the parkinsonian group was subdivided into nondemented and demented patients. These data indicate that VIP-containing neurons are not affected in parkinsonian patients. Our results also suggest that VIP neuronal systems are not involved in the course of dementing process in Parkinson's disease.

UI MeSH Term Description Entries
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014660 Vasoactive Intestinal Peptide A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE). VIP (Vasoactive Intestinal Peptide),Vasoactive Intestinal Polypeptide,Vasointestinal Peptide,Intestinal Peptide, Vasoactive,Intestinal Polypeptide, Vasoactive,Peptide, Vasoactive Intestinal,Peptide, Vasointestinal,Polypeptide, Vasoactive Intestinal

Related Publications

S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
June 1987, Brain research,
S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
October 1989, Journal of neurochemistry,
S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
September 1986, Thorax,
S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
February 1987, Allergy,
S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
January 1995, Biological signals,
S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
April 1994, Zhonghua yi xue za zhi,
S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
December 1987, The American journal of cardiology,
S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
January 1984, Peptides,
S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
June 1992, Neuroscience,
S Jégou, and F Javoy-Agid, and C Delbende, and D Tranchand-Bunel, and D H Coy, and Y Agid, and H Vaudry
November 2012, Journal of molecular neuroscience : MN,
Copied contents to your clipboard!